Skip to main
DGX

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 23%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics has demonstrated robust performance, with total revenue reaching $2.82 billion, reflecting a year-over-year growth of 13.1% and exceeding both internal and consensus estimates. The company reported a remarkable increase in cash flow from operations, up 63.1% year-over-year, bolstered by higher operating income and strategic benefits from recent initiatives. Additionally, the strong expansion in both physician and consumer-initiated testing channels highlights broad-based demand, with significant growth opportunities in advanced diagnostics and partnerships further supporting the positive outlook for the company's financial health.

Bears say

The negative outlook on Quest Diagnostics's stock stems from its reliance on clinical testing, which generates over 95% of its revenue, indicating vulnerability to fluctuations in demand and market conditions. Additionally, the reference to a pricing target based on an 18.0x multiple of 2027E adjusted EPS suggests concerns about the company's future earnings potential in a competitive environment. Lastly, the note about a marginal benefit from weather and a global IT outage in the prior year quarter may imply that past performance improvements could be unsustainable, raising doubts about consistent revenue growth going forward.

Quest Diagnostics (DGX) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 23% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Hold based on their latest research and market trends.

According to 13 analysts, Quest Diagnostics (DGX) has a Hold consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.